Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis
André Schultz(Princess Margaret Hospital for Children), Tom Snelling(National Centre for Immunisation Research & Surveillance), M. Bellgard(Queensland University of Technology), Peter G. Middleton(The University of Sydney), Benjamin R. Saville(Vanderbilt University), Julie Marsh(The Kids Research Institute Australia), Richard Norman(Curtin University), Hugh Greville(Royal Adelaide Hospital), Scott Berry(Queen's University)
Cited by 11
Related Papers
Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values
|Clinical Chemistry|2007|1.9k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818